Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 1/20 | 0.55 |
| ▸ | CA1 | P00915 | 1/20 | 0.55 |
| ▸ | CA2 | P00918 | 1/20 | 0.55 |
| ▸ | CA7 | P43166 | 1/20 | 0.55 |
| ▸ | CA9 | Q16790 | 1/20 | 0.55 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.55 |
| ▸ | FDPS | P14324 | 1/20 | 0.55 |
| ▸ | MAOB | P27338 | 1/20 | 0.54 |
| ▸ | DPP4 | P27487 | 2/20 | 0.51 |
| ▸ | TTR | P02766 | 1/20 | 0.51 |
| ▸ | NPC1 | O15118 | 1/20 | 0.49 |
| ▸ | RAB9A | P51151 | 1/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.49 |
| ▸ | ACHE | P22303 | 4/20 | 0.44 |
| ▸ | BCHE | P06276 | 3/20 | 0.44 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.44 |
| ▸ | TUBB4A | P04350 | 1/20 | 0.44 |
| ▸ | TUBB | P07437 | 1/20 | 0.44 |
| ▸ | TUBA3C | P0DPH7 | 1/20 | 0.44 |
| ▸ | TUBA1B | P68363 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4416140 | 1.00 | CA12 (0.55) | CA12CA1CA2CA7CA9 | |
| SCHEMBL20153730 | 0.89 | CA12 (0.57) | CA12CA1CA2CA7CA9 | |
| SCHEMBL20153503 | 0.85 | CA12 (0.60) | CA12CA1CA2CA7CA9 | |
| SCHEMBL9889434 | 0.85 | KDM4E (0.54) | CA12CA1CA2CA7CA9 | |
| SCHEMBL20153690 | 0.82 | CA12 (0.57) | CA12CA1CA2CA7CA9 | |
| SCHEMBL1914006 | 0.82 | CA12 (0.57) | CA12CA1CA2CA7CA9 | |
| SCHEMBL1914010 | 0.82 | CA12 (0.57) | CA12CA1CA2CA7CA9 | |
| SCHEMBL30018286 | 0.80 | FDPS (0.61) | CA12CA1CA2CA7CA9 | |
| SCHEMBL3870743 | 0.80 | FDPS (0.61) | CA12CA1CA2CA7CA9 | |
| SCHEMBL20153362 | 0.80 | FDPS (0.61) | CA12CA1CA2CA7CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1479671-B1 | Pyrimidinone compounds | SMITHKLINE BEECHAM PLC (GB) | 2009-05-27 | — | — | EP | disclosed |
| US-7115616-B2 | Pyrimidinone compounds | SMITHKLINE BEECHAM PLC (GB) | 2006-10-03 | — | — | US | disclosed |
| US-6953803-B1 | 1-[(N-(2-(diethylamino)ethyl)-N-(4-(4-trifluoromethylphenyl)benzyl)aminocarbonylmethyl)]-2-(4-fluorobenzyl)thio-5-(1-methyl-4-pyrazolylmethyl)pyrimidin-4-one; enzyme inhibitors of lipoprotein associated phospholipase A2 (Lp-PLA2); atherosclerosis | SMITHKLINE BEECHAM P.L.C. (GB) | 2005-10-11 | — | — | US | disclosed |
| EP-1479671-A1 | Pyrimidinone compounds | SMITHKLINE BEECHAM PLC (GB) | 2004-11-24 | — | — | EP | disclosed |
| US-20040167142-A1 | Pyrimidinone compounds | SMITHKLINE BEECHAM P.L.C. | 2004-08-26 | — | — | US | disclosed |
| EP-1105377-B1 | PYRIMIDINONE DERIVATIVES FOR THE TREATMENT OF ATHEROSCLEROSIS | SMITHKLINE BEECHAM PLC (GB) | 2003-10-08 | — | — | EP | disclosed |
| EP-1028955-B1 | PYRIMIDINONE COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | SMITHKLINE BEECHAM PLC (GB) | 2003-07-16 | — | — | EP | disclosed |
| US-6559155-B1 | Phospholipase A2 enzyme Lipoprotein Associated Phospholipase A2 inhibitors | SMITHKLINE BEECHAM P.L.C. (GB) | 2003-05-06 | — | — | US | disclosed |
| US-20020120139-A1 | Pyrimidinone compounds and pharmaceutical compositions containing them | HICKEY DEIRDRE MARY BERNADETTE (GB) | 2002-08-29 | — | — | US | disclosed |
| US-6417192-B1 | DRUGS WITH PYRIMIDONE COMPOUNDS INHIBITORS OF THE ENZYME LDL PLA.SUB.2 AND THEREFORE OF USE IN TREATING ATHEROSCLEROSIS. | SMITHKLINE BEECHAM P.L.C. (GB) | 2002-07-09 | — | — | US | disclosed |
| EP-1175409-A1 | PYRIMIDINONES DERIVATIVES FOR THE TREATMENT OF ATHEROSCLEROSIS | SMITHKLINE BEECHAM PLC (GB) | 2002-01-30 | — | — | EP | disclosed |
| EP-1175408-A1 | PYRIMIDINONE COMPOUNDS | SMITHKLINE BEECHAM PLC (GB) | 2002-01-30 | — | — | EP | disclosed |
| EP-1105377-A1 | PYRIMIDINONE DERIVATIVES FOR THE TREATMENT OF ATHEROSCLEROSIS | SMITHKLINE BEECHAM PLC (GB) | 2001-06-13 | — | — | EP | disclosed |
| WO-2000068208-A1 | PYRIMIDINONES DERIVATIVES FOR THE TREATMENT OF ATHEROSCLEROSIS | SMITHKLINE BEECHAM PLC (GB) | 2000-11-16 | — | — | WO | disclosed |
| WO-2000066567-A1 | PYRIMIDINONE COMPOUNDS | SMITHKLINE BEECHAM PLC (GB) | 2000-11-09 | — | — | WO | disclosed |
| EP-1028955-A1 | PYRIMIDINONE COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | SmithKline Beecham p.l.c. (GB) | 2000-08-23 | — | — | EP | disclosed |
| WO-2000010980-A1 | PYRIMIDINONE DERIVATIVES FOR THE TREATMENT OF ATHEROSCLEROSIS | SMITHKLINE BEECHAM PLC (GB) | 2000-03-02 | — | — | WO | disclosed |
| WO-1999024420-A1 | PYRIMIDINONE COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | SMITHKLINE BEECHAM PLC (GB) | 1999-05-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020120139-A1 | Pyrimidinone compounds and pharmaceutical compositions containing them | PLA2G7, PLA2G1B, PLA2G4C | CA12 4871/4885CA1 4810/4885CA2 4296/4885 |
| US-20040167142-A1 | Pyrimidinone compounds | LPL, LIPG, PCSK9 | CA12 4278/4885CA1 4243/4885CA2 3152/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.